Quintiles added anatomic pathology to the service offerings it provides at its central laboratory in Beijing, China. The new services complement assay development, digital pathology and core lab offerings, which the Beijing facility already offers to help customers comply with China’s restrictions on tissue import and export.

“Within China, we are providing the tools and infrastructure to investigate cancer and match patients with optimum treatments for their genetic makeup,” said Christopher Ung, Quintiles’ vice president of strategic business and operations, oncology. “These capabilities enable personalized medicine and enhance oncology research to bring medicines to market faster.”

The Beijing anatomic pathology lab also received College of American Pathologists (CAP) accreditation. The central lab at the Beijing site already was CAP-accredited. Quintiles has nine accredited labs—one each in Argentina, Brazil, China, India, Japan, Singapore, Scotland, South Africa and the U.S.